Gender aspects suggestive of gastroparesis in patients with diabetes mellitus: a cross-sectional survey by Ram Dickman et al.
Dickman et al. BMC Gastroenterology 2014, 14:34
http://www.biomedcentral.com/1471-230X/14/34RESEARCH ARTICLE Open AccessGender aspects suggestive of gastroparesis in
patients with diabetes mellitus: a cross-sectional
survey
Ram Dickman1,5*†, Julio Wainstein2,5†, Marek Glezerman4,5, Yaron Niv1,5 and Mona Boaz3,5Abstract
Background: It is suggested that symptoms related to gastroparesis are more common in female than in male
patients with type 2 diabetes mellitus (T2DM). The association between sex and prevalence of symptoms
suggestive of gastroparesis among patients with T2DM in Israel has not been reported. The aim of this study was to
describe the associations between sex, clinical characteristics, type, severity and prevalence of dyspeptic symptoms
in a large population of patients with T2DM in Israel.
Methods: All patients completed a demographic questionnaire and the Gastroparesis Cardinal Symptom Index
(GCSI). Data regarding disease duration, medications, complications, recent blood glucose and HbA1c levels were
also collected. In this nested case–control study, 173 female and 209 male patients were identified from within a
cross-sectional survey of 382 patients with T2DM. Logistic and general linear modeling was used to assess
associations between sex, clinical data, and the presence (type and number) of symptoms.
Results: Compared to males, female patients with T2DM had a higher body mass index (BMI) (31.9 vs. 29.2;
P = 0.001) and HbA1c levels (7.9 vs. 7.5; P = 0.04). A larger proportion of males suffered from peripheral vascular
disease (P = 0.02) and ischemic heart disease (P = 0.001). Other disease characteristics did not differ between the
sexes. The prevalence of nausea (P = 0.001), early satiety (P = 0.005), loss of appetite (P = 0.002), or presence of any
cardinal symptom (P = 0.001) was significantly higher among females. Severity of most cardinal symptoms was also
higher in females. The presence of at least one cardinal symptom was more likely among obese females with
longer disease duration and poor glycemic control.
Conclusions: Prevalence and severity of symptoms suggestive of gastroparesis is particularly high among obese
females with long standing and poorly controlled T2DM.
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Gastroparesis is characterized by an abnormal gastric
emptying rate (GER) associated with symptoms, such as
nausea, vomiting, postprandial fullness, early satiety, and
bloating [1,2]. Diabetic gastroparesis (DG) affects patients
with long-standing diabetes mellitus (DM) usually compli-
cated by retinopathy, neuropathy, and nephropathy [1].
DG may cause severe nutritional deficits, and is associated* Correspondence: dickmanr1@gmail.com
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reproduction in any medium, provided the orwith higher morbidity and mortality due to difficulties in
achieving glucose control [1,3]. Early diagnosis of DG
is needed because therapy by strict glucose control,
diet interventions and prokinetics often leads to clinical
improvement [4].
There is no perfect biomarker for dyspeptic symptoms
suggestive of gastric dysmotility, such as DG. In fact,
GER was found to be surprisingly normal in some dyspep-
tic patients with long- term DM, or delayed in asymptom-
atic patients with type 2 DM (T2DM) [5]. Nevertheless, the
current definition for DG still relies on demonstrating de-
layed gastric emptying by gastric scintigraphy in symptom-
atic patients [1,4]. Gastric scintigraphy requires specializedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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diation exposure. Thus, in view of the above, it is reason-
able to pre-select diabetic patients for a further evaluation
by gastric scintigraphy based on the presence of cardinal
symptoms suggestive of DG [2]. Postprandial fullness, early
satiety, bloating, nausea and vomiting have been reported
to be more prevalent in diabetic patients than in the general
population. In a gastric scintigraphy study of 101 patients
with DM, 83% reported upper gastrointestinal symptoms
[6]. Conversely, only 7-15% of subjects in the general popu-
lation reported dyspeptic symptoms [7].
The underlying mechanisms for DG include autonomic
neuropathy, enteric neuropathy, abnormalities of interstitial
cells of Cajal, poor (i.e. acute fluctuations) glucose control,
use of incretin-based medications, and psychosomatic fac-
tors [1]. Females generally have a slower solid and liquid
GER than males [8-10]. The underlying mechanism for this
phenomenon is not fully understood and may be related to
estrogen levels. Indeed, during the ovulatory period and
during pregnancy, females tend to have reduced peristalsis
and increased incidence of intractable constipation.
The aim of the present study was to further investigate
the associations between sex, clinical data, type, severity
and prevalence of cardinal symptoms suggestive of gas-
troparesis in a large population of patients with T2DM
in Israel.
Methods
A cross-sectional survey of 382 consecutive patients with
T2DM, treated in community outpatient clinics, was
performed to estimate the prevalence of gastroparesis.
All patients completed a demographic and lifestyle ques-
tionnaire as well as the validated Hebrew translation of
the Gastroparesis Cardinal Symptom Index (GCSI) [11].
Height and weight were recorded and body mass index
(BMI) was calculated as weight [kg)/(height (m)2]. Disease
duration, prescribed medications, comorbidities, diabetes
complications, most recent blood glucose and HbA1c
levels were extracted from the patients’ medical records.
This community center study was conducted in accor-
dance with the principles of the Declaration of Helsinki
and Good Clinical Practice (GCP) and was approved by
the Human Subjects Protection Program of The Edith
Wolfson Medical Center. All participants provided written
informed consent before enrollment.
Symptom assessment
Patients were asked to rate symptoms suggestive of gastro-
paresis. The GCSI consists of three subscales of the Patient
Assessment of Upper Gastrointestinal Disorders-Symptom
Severity Index PAGI-SYM, selected to measure important
symptoms related to gastroparesis. Symptoms include
nausea/vomiting, postprandial fullness/early satiety, and
bloating [2]. The nausea/vomiting subscale includes thefollowing three items: Nausea, retching, and vomiting.
The postprandial fullness/early satiety subscale is com-
prised of the following four items: Stomach fullness,
inability to finish a normal-sized meal, feeling excessively
full after meals, and loss of appetite. The bloating subscale
is comprised of the following two items: Bloating, and vis-
ibly larger stomach or belly after meals. Overall, the GCSI
comprises 9 questions and each question is rated by the
responder according to severity of symptoms, i.e. from 0
to 5 (0 = no symptoms to 5 = severe symptoms). The total
GCSI score was categorized as “severe” (GCSI > 27) or
“mild” (GCSI ≤ 27).
Definitions
“Cardinal symptoms” included nausea, retching, vomiting,
difficulty completing a normal meal, early satiety, post-
prandial fullness, loss of appetite, bloating, and visible
postprandial abdominal distension. “Obese” was defined
as BMI ≥ 30 kg/m2.
Sample size and study power
The survey cohort included 382 patients with T2DM.
This sample size provided 80% power to detect a true,
by-sex relative difference in the presence of any cardinal
symptom of approximately 15% (assuming a rate of 60%
in males and 70% in females) regarding the presence of
any cardinal symptom. This estimate is based on the chi
square test and assumes a two-sided alpha of 0.05.
Data analysis
Analysis of data was performed with the SPSS 21.0
statistical analysis software (IBM Inc., USA). Distributions
of continuous variables were assessed for normality using
the Kolmogorov-Smirnov test (cutoff at P < 0.01). Nor-
mally distributed continuous variables, such as age,
height and weight were described as mean ± standard
deviation (m ± SD). The t-test for independent samples
or the Mann–Whitney U was used to compare continuous
variables by sex. For categorical variables, such as co-
morbidities and medications, we used frequency distri-
butions, presented as frequency (%). The chi square test
(Fisher's exact as needed) was used to assess associations
between categorical variables and sex. The presence of any
cardinal symptom was modeled using logistic regression
analysis. Odds ratios (ORs) were estimated with 95%
confidence intervals (CIs). All tests were two-sided and
considered significant at P <0.05.
Results
In this study, 173 female and 209 male patients were in-
cluded in the cross-sectional survey of patients with T2DM.
Table 1 describes the clinical characteristics of the study
participants. Compared to males, a greater proportion
of female patients was obese and had poorer glycemic







Age (years)* 63.5±10.1 62.7±11.5 0.48
BMI (kg/cm2)* 31.9±5.2 29.2±9.7 0.001
Obesity (%) 59.0 27.3 <0.0001
Diabetes duration (years)* 14.0±11.9 11.9±8.6 0.05
Fasting blood glucose (mg/dl) * 154.5±64.1 146.1±57.2 0.18
HbA1c (%)* 7.9±1.4 7.5±1.6 0.04
Diabetes complications:
Peripheral vascular disease (%) 12.8 21.5 0.02
Ischemic heart disease (%) 32.0 49.3 0.001
Hypertension (%) 84.2 82.3 0.62
Cerebral vascular accident 9.9 8.1 0.55
Dyslipidemia (%) 86.7 79.9 0.07
Diabetes medications:
Metformin (%) 66.5 60.3 0.21
Sulfonylureas (%) 53.2 56.0 0.58
Acarbose (%) 9.2 11.1 0.56
Rosiglitazone (%) 6.9 12.9 0.05
Exenatide (%) 5.2 4.8 0.85
Insulin (%) 49.1 44.0 0.31
Other medications:
Statins (%) 82.6 79.9 0.51
Alfa blockers (%) 14.0 21.6 0.53
ACE inhibitors (%) 79.7 78.0 0.69
Calcium channel blockers (%) 34.9 28.4 0.17
Beta blockers (%) 47.1 52.2 0.32
Diuretics (%) 36.0 36.8 0.87
Nitrates (%) 13.4 14.8 0.68
Lifestyle characteristics:




Values are expressed as percentage.
*Mean ± standard deviation; Obesity = BMI ≥ 30 kg/cm2.
**P value is for across-group comparison; post hoc testing was conducted for
significant findings.
Table 2 Subject’s prevalence of symptoms suggestive of






Nausea (%) 31.8 31.8 0.001
Retching (%) 9.8 9.8 0.19
Vomiting (%) 6.9 6.9 0.26
Stomach fullness (%) 45.7 45.7 0.17
Early satiety (%) 36.7 36.7 0.001
Feeling excessively full after meals (%) 52.6 52.6 0.005
Loss of appetite (%) 23.1 23.1 0.002
Bloating (%) 53.2 53.2 0.11
Stomach or belly visibly larger (%) 57.8 57.8 0.79
Any symptom (%) 82.1 82.1 0.003
No. of symptoms* 3.4±2.5 3.4 ± 2.5 0.001
*Mean ± standard deviation.
**P value is for across-group comparison; post hoc testing was conducted for
significant findings.
Table 3 Subject’s mean severity score of symptoms






Nausea 0.75 0.38 0.002
Retching 0.18 0.11 0.20
Vomiting 0.13 0.09 0.44
Stomach fullness 1.32 1.00 0.04
Early satiety 0.89 0.47 0.001
Feeling excessively full after meals 1.57 1.06 0.002
Loss of appetite 0.53 0.24 0.003
Bloating 1.60 1.02 0.013
Stomach or belly visibly larger 1.78 1.32 0.009
Values are expressed as mean ± standard deviation.
*P value is for across-group comparison; post hoc testing was conducted for
significant findings.
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vascular disease and ischemic heart disease. Other by-sex
clinical differences were not significant. Self-reported
adherence to dietary counseling was similar but the pro-
portion of patients reporting regular exercise was lower
among females.
Prevalence and severity of symptoms by gender
The prevalence and severity of the reported cardinal symp-
toms were compared by sex in Tables 2 and 3, respectively.Females patients reported significantly more nausea
(P = 0.001), early satiety (P = 0.001), feeling excessively full
after meals (P = 0.005), and loss of appetite (P = 0.002).
Sex differences in retching, vomiting, stomach fullness,
bloating, and visibly larger stomach or belly after meals
were not detected (Table 3). The reported severity of most
symptoms (except for retching and vomiting) was also
significantly higher among females (Table 3). The pres-
ence of at least one cardinal symptom was more likely
among female patients who reported (of more) other
symptoms as well.
Associations between symptoms and disease
characteristics
A logistic regression model (Table 4) was developed to
assess factors that predict symptoms. Sex, age, diabetes
Table 4 Logistic regression of any symptom suggestive of
gastroparesis
OR 95% CI P value
BMI 1.026 0.981-1.074 0.277
Female sex 1.838 1.099-3.074 0.020
Age 1.013 0.990-1.069 0.209
HbA1c 1.093 0.922-1.297 0.306
Disease duration 1.026 0.998-1.056 0.073
BMI body mass index.
Dickman et al. BMC Gastroenterology 2014, 14:34 Page 4 of 5
http://www.biomedcentral.com/1471-230X/14/34duration, HbA1c levels and BMI were included in the
model. The model was significant (P < 0.0001) and cor-
rectly categorized 75% of study participants as having
at least one gastroparesis symptom. Specifically, female
sex increased symptom risk by 83.8%: OR 1.838, 95%
CI 1.099-3.074, P = 0.02.
Discussion
In the present study, female patients with T2DM reported
more dyspeptic symptoms that may suggest gastroparesis.
We also found that the symptom severity scores were
higher among females. Other studies that evaluated gas-
tric emptying in patients with T2DM found that females
tend to have a slower GER [8,9,12,13]. Furthermore, in an
ongoing research study by our group, a significantly greater
proportion of age-matched female patients without T2DM
(control group) were found to have a slower GER for solids
than females with T2DM. This finding too may suggest
a sex-relative effect on GER as observed in this study.
The underlying mechanism for this phenomenon is not
fully understood and seems multifactorial. In humans, the
slower gastric motility in females may be attributable to
estrogen levels. Reduction in sex steroid hormones may
down regulate NOS-mediated gastric motility leading to
gastroparesis in diabetic females [10]. However, in our
study, most of the females with T2DM were in their 6th
decade of life indicating low, rather than normal or high
estrogen levels. Unfortunately, we have insufficient infor-
mation related to hormonal replacement therapy (HRT),
that some of our female patients might have received.
Consequently, a conclusion regarding the probable effect
of estrogen (based on reports of HRT prescriptions) could
not be drawn.
In the present study, most females with T2DM were
obese. According to the results of a recent study, it was
suggested that obesity could play a significant role in
estrogen receptor gene expression [14]. It is the adipose
tissue of obese vs non-obese females that secretes more
biologically active estrogen. Thus, we may only speculate
that in our obese female patients with T2DM, biologically
active estrogen and estrogen receptor gene expression were
higher than in non-obese patients. Finally, even if there
are sex differences in gastric emptying, perhaps mediatedby estrogen levels, the generally low prevalence of delayed
emptying in symptomatic individuals makes it highly
unlikely that a sex-dependent phenomenon is the only
mechanism that affects gastric emptying.
Our findings must be considered in light of the study’s
limitations. Cardinal symptoms were suggestive of gastro-
paresis, but this condition was not objectively diagnosed by
gastric scintigraphy. Rey et al. [15] recently assessed the
possible presence of gastroparesis in the general population.
Instead of dichotomizing based on mere symptom presence
as performed in our study, these authors examined the
presence of documented gastroparesis in a clinic sample,
and correlated symptom scores with presence of gastropar-
esis. While questionable (delayed gastric emptying poorly
correlates with symptoms), they used these data to predict
the presence of gastroparesis based on weighted symptom
severity scores. Not surprisingly, the prevalence was slightly
lower, as they dealt with a clinic population and had a
higher threshold for case identification. Nevertheless, Rey
et al. concluded that since the prevalence of diagnosed
gastroparesis is low, many subjects with gastroparesis may
remain undiagnosed. As the data presented in our study
do not include a sample with clinical and gastric emptying
data, we can only discuss symptoms suggestive of gastro-
paresis rather than diagnosed gastroparesis. As mentioned,
gastroparesis is defined by demonstrating delayed gastric
emptying in a symptomatic patient [4]. However, as the
correlation between subjective and objective evidence for
gastroparesis is poor in patients with DM, we believe that
the absence of an imperfect biomarker, such as a gastric
scintigraphy, may not be a real weakness.
Though symptoms may be attributed to conditions
other than gastroparesis, such as functional gastrointes-
tinal disorders, identifying the elevated prevalence of
these symptoms among diabetic patients is important
for the clinical practitioner. Firstly, knowledge regarding
the prevalence of a condition in a given population permits
the clinician to consider prior probability when encounter-
ing these symptoms in a specific individual. Secondly,
knowing that symptoms are common within certain patient
groups can serve to reassure the anxious patient.
Another limitation is that our study was conducted in a
convenience sample of individuals, and not in a probability
sample of all patients with DM. This makes generalization
to the target population challenging. Nevertheless, the size
and source (a large community-based clinic) of the study
population and its composition suggests a robustness of
findings. An additional important weakness is related to the
study criteria for illness definition that may be set too low.
In fact, with a relatively minor symptom severity and no
indicators of symptom duration, many of our patients may
not fulfill current consensus criteria for functional dyspep-
sia. Furthermore, important confounders in our study
may play a significant role in explaining the results.
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multiple treatments, such as calcium channel blockers
(constipation and bloating), acarbose (bloating) and exena-
tide (nausea). Thus, we may not be dealing with a second-
ary consequence of DM, but rather the consequence of
treating disease. Finally, we could not discuss the probable
effect of estrogen level based on reports of HRT prescrip-
tions as this information was unavailable for most of our
females. Nevertheless, as most of the symptomatic females
were obese, we may still speculate (based on our model)
that estrogen level and receptor gene expression were
higher in our female patients with T2DM.
The identification of obesity as a risk factor for gastro-
paresis symptoms in females with T2DM provides an
opportunity for intervention, and suggests that weight loss
may improve symptoms, especially in this patient popula-
tion [16]. A controlled clinical trial designed to examine
this intervention is the next logical step.Conclusions
The prevalence and severity of symptoms suggestive of
gastroparesis among patients with T2DM is higher in
females than in males. This association persists even after
controlling for disease duration, age, HbA1c percentage
and BMI. These findings suggest that when treating
patients with T2DM, physicians may want to screen for
gastric symptoms suggestive of gastroparesis using the
GCSI. This seems particularly relevant for female patients.Abbreviations
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